C
Cibus Inc
NASDAQ:CBUS
Cibus Inc
NASDAQ:CBUS
Price:
17.77 USD
-3.95%
Market Closed
Updated:
May 21, 2024
Section:
Relative Value
The Relative Value of one CBUS stock under the Base Case scenario is 15.25 USD. Compared to the current market price of 17.77 USD, Cibus Inc is Overvalued by 14%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CBUS
Relative Value
Base Case
15.25
USD
Overvaluation 14%
C
Valuation Multiples
Multiples Across Competitors
CBUS Competitors Multiples
Cibus Inc Competitors
Cibus Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
C
|
Cibus Inc
NASDAQ:CBUS
|
440.2m USD | 189.1 | -1.5 | -1.3 | -1.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
290.6B USD | 5.3 | 48.8 | 13.7 | 21.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.7B USD | 5.7 | 44.8 | 18.8 | 31.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 11.3 | 28.7 | 24 | 25.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.8B USD | 8.3 | 28.2 | 22.8 | 25.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 3.1 | 174.8 | 8.8 | 11.6 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54B USD | 10.5 | -9 | -10.1 | -9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.7B USD | 3.5 | 28.9 | 14.7 | 18.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.7T KRW | 17.8 | 72.3 | 44.3 | 61 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
